▽The New England Journal of Medicine: Research & Review Articles on Diseases & Clinical Practice ●02/09 10:36 Feb 07, 2025Meeting of the World Congress of NephrologyObinutuzumab in Active Lupus NephritisR.A. Furie and OthersIn this trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis.Original ArticleFeb 07, 2025Meeting of the World Congress of Nephrolog